替莫唑胺
胶质瘤
甲基转移酶
癌症研究
体内
DNA修复
DNA损伤
细胞毒性
细胞凋亡
O-6-甲基鸟嘌呤-DNA甲基转移酶
达卡巴嗪
化疗
药理学
生物
体外
医学
DNA
黑色素瘤
内科学
生物化学
甲基化
生物技术
作者
Haoyue Xu,Yongkang Zhang,Linfeng Li,Yanhong Ren,Feng Qian,Lansheng Wang,Hongwei Ma,Ankang Quan,Hongmei Liu,Rutong Yu
出处
期刊:Drug Delivery
[Taylor & Francis]
日期:2022-12-29
卷期号:30 (1): 1-13
被引量:7
标识
DOI:10.1080/10717544.2022.2152911
摘要
Temozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties. O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme, which can repair the DNA damage caused by TMZ. A large number of clinical data show that reducing the expression of MGMT can enhance the chemotherapeutic efficacy of TMZ. Therefore, in order to improve the resistance of glioma to TMZ, an angiopep-2 (A2) modified nanoprodrug of polytemozolomide (P(TMZ)n) that combines with MGMT siRNA (siMGMT) targeting MGMT was developed (A2/T/D/siMGMT). It not only increased the amount of TMZ within tumor lesion site, but also reduced MGMT expression in glioma. The in vitro experiments indicated that the A2/T/D/siMGMT effectively enhanced the cellular uptake of TMZ and siMGMT, and resulted in a significant cell apoptosis and cytotoxicity in the glioma cells. The in vivo experiments showed that glioma growth was inhibited and the survival time of animals were prolonged remarkably after A2/T/D/siMGMT was injected via tail vein. The results showed that the therapeutic effect of A2/T/D/siMGMT in the treatment of glioma was significantly improved.
科研通智能强力驱动
Strongly Powered by AbleSci AI